

Hartford Healthcare Fund

Tickers A: HGHAX C: HGHGX F: HGHFX I: HGHIX R3: HGHXR R4: HGHXS R5: HGHTX R6: HGHVX Y: HGHYX

Morningstar® Category Health **Inception Date** 5/01/00

Market Overview

The S&P Composite 1500 Health Care Index rose +5.54% during the quarter, outperforming the broader US market, as measured by the S&P 500 Index (-4.27%). Within the benchmark, healthcare-services stocks outperformed the most, while small-cap biopharma stocks underperformed during the period.

Performance Summary

- The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter.
- Security selection was the driver of relative underperformance as selection within large-cap biopharma and medical technology detracted most.
- Sub-sector allocation, a result of our bottom-up stock-selection process, detracted from relative performance. Allocation effect was driven by our overweight to mid-cap biopharma.
- At the issuer level, our top-two relative detractors were an underweight to AbbVie and not owning CVS Health, while our top-two relative contributors were overweights to Alignment Healthcare and Cencora.

Positioning & Outlook

- Biopharma remains a rich environment for innovation. We are excited about developments in GLP-1 and next-generation metabolic medicines, antibody drug conjugates for cancer treatment, and various modalities of genetic medicines. The range of outcomes for stocks remains wide as we await clarity on the US administration's tariff and drug-pricing policies. US drug prices may gradually decrease over time, but we think pricing risks are manageable, and we find opportunities in companies with rich pipelines and track records of productive business development. We are monitoring organizational changes at the US Food and Drug Administration to evaluate their potential impact on the timing and standards of new drug approvals. We are underweight large-cap biopharma but selectively adding to companies with lower valuations, downside support and reaccelerating growth opportunities. Select SMID-cap biopharma companies remain well-positioned, and ultimately, the successful development of new drugs that address significant unmet medical needs should drive value creation.
- We believe medical-technology innovation has never been stronger due to advancements in technology development, engineering capabilities, and integrated informatics. Areas of most interest include interventional cardiology, robotics, and a reacceleration in the bioproduction cycle. We remain disciplined around valuation and selective in our exposures.
- Healthcare-services companies are well-positioned to help solve the challenge of rising healthcare costs and to benefit from the transition from a fee-for-service to a fee-for-value care system. We see attractive risk-reward in Medicare Advantage companies as valuations are low and profitability has troughed across government-insurance programs. A favorable final rate notice could be a positive catalyst. Providers should benefit from higher utilization and behavioral health companies have bipartisan political support in the US. We favor companies focused on improving patient outcomes while reining in costs and scaled players with rising market share.

Portfolio managers from Wellington Management and years of experience

Rebecca Sykes, CFA, 20 years
Wen Shi, CFA, 18 years
David Khtikian, CFA, 26 years
Samuel Bitetti, CFA, 18 years

Top Ten Holdings (%)

Eli Lilly & Co.	13.05
UnitedHealth Group, Inc.	10.08
Boston Scientific Corp.	4.76
Merck & Co., Inc.	3.94
Intuitive Surgical, Inc.	3.39
Vertex Pharmaceuticals, Inc.	2.96
Thermo Fisher Scientific, Inc.	2.79
Johnson & Johnson	2.54
Cencora, Inc.	2.51
AbbVie, Inc.	2.45

Percentage Of Portfolio **48.47**

Holdings and characteristics are subject to change. Percentages may be rounded.

Average Annual Total Returns (%)

Class	QTD	YTD	1 Year	3 Year	5 Year	10 Year	SI	Expenses ¹	
								Gross	Net
A	0.57	0.57	-6.34	-0.09	7.48	6.27	10.15	1.29%	1.29%
A with 5.5% Max Sales Charge	—	—	-11.49	-1.95	6.27	5.67	9.91	—	—
F	0.68	0.68	-6.02	0.28	7.87	6.64	10.43	0.92%	0.92%
I	0.66	0.66	-6.11	0.18	7.77	6.56	10.40	1.02%	1.02%
R3	0.48	0.48	-6.68	-0.43	7.11	5.92	10.07	1.63%	1.63%
R4	0.56	0.56	-6.39	-0.12	7.44	6.24	10.33	1.31%	1.31%
R5	0.64	0.64	-6.12	0.16	7.75	6.55	10.57	1.04%	1.04%
R6	0.67	0.67	-6.03	0.27	7.86	6.66	10.65	0.92%	0.92%
Y	0.62	0.62	-6.12	0.17	7.77	6.61	10.63	1.03%	1.03%
Benchmark	5.54	5.54	-0.13	3.29	11.91	9.02	—	—	—
Morningstar Category	-1.46	-1.46	-6.28	-1.28	6.84	5.31	—	—	—

Morningstar® Category Health

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

Share Class Inception: A, Y - 5/1/00; F - 2/28/17; I - 8/31/06; R3, R4, R5 - 12/22/06; R6 - 2/28/19. Performance shown prior to the inception of a class reflects performance and operating expenses of another class(es) (excluding sales charges, if applicable). Had fees and expenses of a class been reflected for the periods prior to the inception of that class, performance would be different. Since inception (SI) performance is from 5/1/00. Performance and expenses for other share classes will vary. Additional information is in the prospectus. Only Class A assesses a sales charge. Performance for periods of less than one year is not annualized.

Benchmark: S&P Composite 1500 Health Care Index comprises those companies included in the S&P Composite 1500 that are classified as members of the GICS health care sector. Indices are unmanaged and not available for direct investment.

¹Expenses are the total annual operating expenses from the Fund's most recent prospectus at the time of publication.

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • The securities of large market capitalization companies may underperform other segments of the market. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments.

Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in a fund's full prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). Certain funds are sub-advised by Wellington Management Company LLP. HFMC and Wellington Management are SEC registered investment advisers. HFD and HFMC are not affiliated with any sub-adviser.